Table 1.
Demographic and clinical characteristics, and functional parameters of the patients
| Mean (min-max) or n (%) | |
|---|---|
| Demographic features | |
| Sex (male/female), n (%) | 43/20 (68.3/31.7) |
| Age (years) | 41.42 (18–68) |
| Anthropometric features | |
| BMI (kg/m2) | 21.87 (12–34) |
| Diagnosis, n (%) | |
| Alveolar proteinosis | 1 (1.6) |
| Bronchiectasis | 26 (41.3) |
| Cystic fibrosis | 5 (7.9) |
| COPD | 15 (23.8) |
| ILD | 7 (11.1) |
| Silicosis | 5 (7.9) |
| Sarcoidosis | 2 (3.2) |
| RA lung involvement | 1 (1.6) |
| NIMV use | |
| Yes, n (%) | 13 (20.6) |
| No, n (%) | 50 (79.4) |
| Receiving systemic corticosteroid therapy | |
| Yes, n (%) | 10 (15.9) |
| No, n (%) | 53 (84.1) |
| mMRC (0–4) | 3 (1–4) |
| Pulmonary function test | |
| FVC, lt | 1.55 (.29–3.09) |
| FVC% | 40.65 (6.3–76.00) |
| FEV1, lt | 1.02 (.40–2.46) |
| FEV1% | 32.33 (10–64) |
| FEV1/FVC | 67.63 (35–110) |
| Respiratory muscle strenght (cmH2O) | |
| MIP | 76.50 (12–129) |
| MEP | 121.12 (47–229) |
| Muscle strenght (lbs)* | |
| QF | 42.41 (14–74) |
| Iliopsoas | 41.63 (16–74) |
| Tibialis anterior | 45.26 (11–91) |
| 6MWD (m) | 336.83 (42–548) |
| 10MWT (sc) | 8.45 (4.44–21.03) |
| 5XSST (sc) | 11.59 (3.96–32.98) |
BMI: body mass index; FFM: fat free mass; ILD: interstitial lung disease; COPD: Chronic obstructive pulmonary disease; RA: Rheumatoid arthritis; NIMV: Non-invasive mechanic ventilation; mMRC: modified Medical Research Council dyspnea score; FVC: forced vital capacity; FEV1: Forced expiratory volume in one second; MIP: Maximum İnspiratory pressure; MEP: Maximum expiratory pressure; QF: Quadriceps femoris muscle strength; 6MWD: 6-minute walking distance; 10MWT: 10-meter walking speed test; 5XSST: 5-times sit-to-stand test
*
Dominant side assessments are given